241 related articles for article (PubMed ID: 16511518)
41. Therapy on trial.
Hughes V
Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
[No Abstract] [Full Text] [Related]
42. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells.
De Palma M; Montini E; Santoni de Sio FR; Benedicenti F; Gentile A; Medico E; Naldini L
Blood; 2005 Mar; 105(6):2307-15. PubMed ID: 15542582
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
44. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.
Dunbar CE
Ann N Y Acad Sci; 2005 Jun; 1044():178-82. PubMed ID: 15958711
[TBL] [Abstract][Full Text] [Related]
45. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
46. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.
Mantovani J; Charrier S; Eckenberg R; Saurin W; Danos O; Perea J; Galy A
J Gene Med; 2009 Aug; 11(8):645-54. PubMed ID: 19455589
[TBL] [Abstract][Full Text] [Related]
47. Common fragile site FRA11G and rare fragile site FRA11B at 11q23.3 encompass distinct genomic regions.
Fechter A; Buettel I; Kuehnel E; Savelyeva L; Schwab M
Genes Chromosomes Cancer; 2007 Jan; 46(1):98-106. PubMed ID: 17063465
[TBL] [Abstract][Full Text] [Related]
48. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
49. Common fragile sites and cancer: targeted cloning by insertional mutagenesis.
Büttel I; Fechter A; Schwab M
Ann N Y Acad Sci; 2004 Dec; 1028():14-27. PubMed ID: 15650228
[TBL] [Abstract][Full Text] [Related]
50. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
51. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.
Pizzato M; Merten OW; Blair ED; Takeuchi Y
Gene Ther; 2001 May; 8(10):737-45. PubMed ID: 11420637
[TBL] [Abstract][Full Text] [Related]
52. Vector integration: location, location, location.
Mok HP; Lever AM
Gene Ther; 2005 Jan; 12(1):1-2. PubMed ID: 15510174
[No Abstract] [Full Text] [Related]
53. Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model.
Schüle S; Steidl S; Panitz S; Coulibaly C; Kalinke U; Cichutek K; Schweizer M
Virology; 2006 Jul; 351(1):237-47. PubMed ID: 16650881
[TBL] [Abstract][Full Text] [Related]
54. A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer.
Seggewiss R; Dunbar CE
J Clin Invest; 2005 Aug; 115(8):2064-7. PubMed ID: 16075048
[TBL] [Abstract][Full Text] [Related]
55. Genome-wide analysis of retroviral DNA integration.
Bushman F; Lewinski M; Ciuffi A; Barr S; Leipzig J; Hannenhalli S; Hoffmann C
Nat Rev Microbiol; 2005 Nov; 3(11):848-58. PubMed ID: 16175173
[TBL] [Abstract][Full Text] [Related]
56. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
57. Success and setback: another adverse event.
Verma IM
Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
[No Abstract] [Full Text] [Related]
58. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Westwood JA; Murray WK; Trivett M; Shin A; Neeson P; MacGregor DP; Haynes NM; Trapani JA; Mayura-Guru P; Fox S; Peinert S; Honemann D; Prince HM; Ritchie D; Scott AM; Smyth FE; Smyth MJ; Darcy PK; Kershaw MH
Gene Ther; 2008 Jul; 15(14):1056-66. PubMed ID: 18369322
[TBL] [Abstract][Full Text] [Related]
59. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
[TBL] [Abstract][Full Text] [Related]
60. Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites.
Joosten M; Vankan-Berkhoudt Y; Tas M; Lunghi M; Jenniskens Y; Parganas E; Valk PJ; Löwenberg B; van den Akker E; Delwel R
Oncogene; 2002 Oct; 21(47):7247-55. PubMed ID: 12370816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
